shutterstock_1565034001_jhvephoto
JHVEphoto / Shutterstock.com
16 November 2020Americas

Baxter sues B.Braun in revived kidney treatment patent dispute

American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
31 August 2017   The Federal Trade Commission has approved a final order combating the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’s injectable drugs business.
Americas
31 July 2014   Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.
Medtech
11 March 2021   The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents.

More on this story

Medtech
11 March 2021   The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents.
Americas
31 July 2014   Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.
Americas
31 August 2017   The Federal Trade Commission has approved a final order combating the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’s injectable drugs business.

More on this story

Medtech
11 March 2021   The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents.
Americas
31 July 2014   Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.
Americas
31 August 2017   The Federal Trade Commission has approved a final order combating the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’s injectable drugs business.